New nanoparticle imaging trial aims to light up hidden tumors

NCT ID NCT06977126

Recruiting now Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This first-in-human trial is testing whether tiny particles called porphysomes can safely improve PET/CT imaging for women with advanced gynecological cancers. The study will enroll 24 participants to find the best dose and check for side effects. It is not a treatment, but a way to potentially see tumors more clearly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: porphysome nanoparticles (a type of tiny particle that can be seen on PET/CT scans)
What this could lead to: If successful, this could lead to a new way to see tumors more clearly in scans, helping doctors better understand where cancer has spread.
What could go wrong: This is a very early, small trial (24 people) focused on safety and dosing, not on treating cancer. The nanoparticles may not work as hoped for imaging, and there could be unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNECOLOGICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female reproductive organ cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GYNECOLOGICAL CANCERS

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.